URINARY-EXCRETION OF MODIFIED NUCLEOSIDES IN CHRONIC MYELOGENOUS LEUKEMIA

  • 1 January 1983
    • journal article
    • research article
    • Vol. 101  (5) , 783-792
Abstract
Urinary excretion of modified nucleosides was measured in 15 patients with Philadelphia chromosome-positive CML [chronic myelogenous leukemia] to determine the correlation with activity of this disease. Resolution and quantitation of 7 nucleosides were accomplished with reversed-phase HPLC [high-performance liquid chromatography]. Patients in the stable phase of CML had excretion levels 1-2 times normal, whereas patients in the blastic phase showed elevations up to 12 times normal. The nucleosides showing the most significant differences in excretion between stable phase and blastic phase were 1-methylinosine, pseudouridine and N2,N2-dimethylguanosine (P < 0.01, P < 0.001 and P < 0.01, respectively). Nucleoside excretion was also determined in patients with bacterial pneumonia and urinary tract infection for comparison. Serial nucleoside determinations made in 2 patients with CML correlated closely with disease activity. The degree of elevation and the correlation with disease activity suggest the potential value of urinary nucleoside quantitation in monitoring patients with CML; in particular, nucleoside excretion may be useful in detecting early blastic transformation.

This publication has 0 references indexed in Scilit: